Jayeon Song, Mi Hyeon Cho, Hayoung Cho, Younseong Song, Sung Woon Lee, Ho Chul Nam, Tae Ho Yoon, Jong Cheol Shin, Jae-Sang Hong, Yejin Kim, Emil Ekanayake, Jueun Jeon, Dong Gil You, Sung Gap Im, Gyu-Seog Choi, Jun Seok Park, Bob C. Carter, Leonora Balaj, An Na Seo, Miles A. Miller, Soo Yeun Park, Taejoon Kang, Cesar M. Castro, Hakho Lee
{"title":"Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE","authors":"Jayeon Song, Mi Hyeon Cho, Hayoung Cho, Younseong Song, Sung Woon Lee, Ho Chul Nam, Tae Ho Yoon, Jong Cheol Shin, Jae-Sang Hong, Yejin Kim, Emil Ekanayake, Jueun Jeon, Dong Gil You, Sung Gap Im, Gyu-Seog Choi, Jun Seok Park, Bob C. Carter, Leonora Balaj, An Na Seo, Miles A. Miller, Soo Yeun Park, Taejoon Kang, Cesar M. Castro, Hakho Lee","doi":"10.1038/s41587-024-02426-6","DOIUrl":null,"url":null,"abstract":"<p>Sequencing of messenger RNA (mRNA) found in extracellular vesicles (EVs) in liquid biopsies can provide clinical information such as somatic mutations, resistance profiles and tumor recurrence. Despite this, EV mRNA remains underused due to its low abundance in liquid biopsies, and large sample volumes or specialized techniques for analysis are required. Here we introduce Self-amplified and CRISPR-aided Operation to Profile EVs (SCOPE), a platform for EV mRNA detection. SCOPE leverages CRISPR-mediated recognition of target RNA using Cas13 to initiate replication and signal amplification, achieving a sub-attomolar detection limit while maintaining single-nucleotide resolution. As a proof of concept, we designed probes for key mutations in <i>KRAS</i>, <i>BRAF</i>, <i>EGFR</i> and <i>IDH1</i> genes, optimized protocols for single-pot assays and implemented an automated device for multi-sample detection. We validated SCOPE’s ability to detect early-stage lung cancer in animal models, monitored tumor mutational burden in patients with colorectal cancer and stratified patients with glioblastoma. SCOPE can expedite readouts, augmenting the clinical use of EVs in precision oncology.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"8 1","pages":""},"PeriodicalIF":33.1000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41587-024-02426-6","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sequencing of messenger RNA (mRNA) found in extracellular vesicles (EVs) in liquid biopsies can provide clinical information such as somatic mutations, resistance profiles and tumor recurrence. Despite this, EV mRNA remains underused due to its low abundance in liquid biopsies, and large sample volumes or specialized techniques for analysis are required. Here we introduce Self-amplified and CRISPR-aided Operation to Profile EVs (SCOPE), a platform for EV mRNA detection. SCOPE leverages CRISPR-mediated recognition of target RNA using Cas13 to initiate replication and signal amplification, achieving a sub-attomolar detection limit while maintaining single-nucleotide resolution. As a proof of concept, we designed probes for key mutations in KRAS, BRAF, EGFR and IDH1 genes, optimized protocols for single-pot assays and implemented an automated device for multi-sample detection. We validated SCOPE’s ability to detect early-stage lung cancer in animal models, monitored tumor mutational burden in patients with colorectal cancer and stratified patients with glioblastoma. SCOPE can expedite readouts, augmenting the clinical use of EVs in precision oncology.
期刊介绍:
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.